Merck Advances Pediatric Oncology with Innovative ADC Modeling
Merck leveraged ADC modeling and pediatric ADC dose optimization to enable FDA acceptance and advance…
Certara2025年12月12日
Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings
Certara launches an expedited Pharmacometrics (PMx) Regulatory Submission service that cuts submission timelines in half.
Certara2025年12月3日
Using M&S to Evaluate Oncology Drug Dosing
Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…
Certara2025年11月14日
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema
Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…
Certara2025年11月12日
Supporting KalVista’s NDA Submission for a Novel HAE Treatment
To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…
Danielle Pillsbury2025年11月12日
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling
Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…
Certara2025年11月10日
Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient
Watch the on-demand webinar on avoiding drug launch failure. Learn how smarter development, evidence, and…
Certara2025年11月6日
Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis
Bridge across studies with Model-based Meta Analysis, incorporating broader data & synthetic patients to enhance…
Certara2025年10月31日
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
Certara2025年10月2日
